The disclosure of the third quarterly report is imminent, who are the ones that are expected to be happy for the performance of the sci-tech innovation board drug companies?

According to regulations, listed companies must complete the three quarterly report performance disclosure before October 31
.
Since October this year, listed companies have entered the three quarterly report performance disclosure period
.
According to incomplete statistics, as of October 11, 13 sci-tech innovation board companies have disclosed their performance forecasts for the first three quarters, of which 10 stocks are pre-happy, accounting for more than 70%, and the overall performance is relatively good
.
Among these 10 companies with pre-performing performance, there are sci-tech board drug companies
.
It is reported that Botuo Bio, which focuses on the field of POCT (point-of-care), predicts that the achievable operating income from January to September 2021 will be between 1.
51 billion yuan and 1.
86 billion yuan, an increase of 136.
18%-190.
93% compared to the same period in 2020; The net profit achieved was 718 million to 875 million yuan, an increase of 101.
27%-145.
45% compared with the net profit of the same period in 2020
.
The company said that the main reason for the growth in performance was that the epidemic continued to repeat around the world, and the sales scale of the company's testing products in the United Kingdom and other overseas regions continued to grow
.
Public information shows that Botuo Bio will be listed on the Science and Technology Innovation Board on September 8, 2021.
It is a company specializing in the research and development, production and sales of POCT diagnostic reagents.
The company's existing products cover infectious disease detection and drug abuse (drug) detection.
, Tumor marker detection, myocardial marker detection, and reproductive health detection are five major detection areas, which are widely used in medical institutions at all levels at home and abroad, judicial detection systems, disease prevention and control centers, and private clinics
.
It is worth mentioning that there are also situations in which pharmaceutical companies are expected to continue to lose, slightly reduce, or pre-cut
.
For example, Shanghai Yizhong-U expects to continue to lose money in the first three quarters of 2021 and realize net profit attributable to shareholders of the parent company of approximately -22 million to -25 million
.
Shanghai Yizhong was officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on September 9 this year
.
The company said that paclitaxel micelles are still in the review stage of registration and listing applications and have not yet achieved commercial production and sales
.
According to the scheduled disclosure schedule of the third quarterly report of the Sci-tech Innovation Board, the first “transcript” of the third quarterly report will be released by Frontier Biotech on October 16th.

.
Public information shows that Frontier Bio is an innovative drug company listed in accordance with the fifth set of listing standards, and the company is not yet profitable
.
The 2021 semi-annual report shows that Frontier Bio has achieved operating income of 22,811,400 yuan, an increase of 233.
14% year-on-year; R&D investment of 56.
026 million yuan, accounting for 245.
61% of operating income
.
It is understood that Frontier Bio's high growth performance in the first half of 2021 is mainly due to the increase in sales revenue of its product Akening
.
Guosheng Securities released a research report on October 8 and maintained its buy rating on Frontier Biotech
.
Guosheng Securities predicts that the net profit of Frontier Biotech attributable to its parent will be 299 million yuan in 2021, a year-on-year decrease of 29.
59%
.
Zhongtai Securities said it is optimistic about the investment opportunities in the equity market in the fourth quarter and believes that the Science and Technology Innovation Board will also perform well
.
Under the premise of common prosperity, relevant policy reforms were implemented in the fourth quarter or continued to increase
.
The agency recommends paying attention to: focusing on the vigorous development of private enterprises, specializing in special new "little giants", the main line of the Beijing Stock Exchange's capital market reform, brokerages and venture capital companies that have deployed financial opening income, high-prosperity specializing in special new enterprises, and Related subjects benefiting from the vigorous development of private enterprises
.
Industrial Securities also recently pointed out that after experiencing the "bottom top" turbulence, Science and Technology has now reached a point in time worthy of dips and bottom digging
.
Prior to this, funds concentrated in the cycle resource product sector, but as the demand side declines in the future, the market >
.
In the medium and long term, the business direction of science and technology innovation, "specialization, specialization, and innovation" is still determined, and the market is still in the ascendant
.